Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

ELCYS

CYSTEINE HYDROCHLORIDE

Standard Dose
2500MG/50ML (50MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Discontinued
Summary

Approval overview ELCYS is listed in Drugs@FDA under application 210660 (NDA).

Review priority: N/A Marketing status: Discontinued Active ingredient CYSTEINE HYDROCHLORIDE Form and strength SOLUTION;INTRAVENOUS - 2500MG/50ML (50MG/ML) Sponsor EXELA PHARMA Submission history Latest submission status date: 2023-12-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview ELCYS is listed in Drugs@FDA under application 210660 (NDA). Review priority: N/A Marketing status: Discontinued Active ingredient CYSTEINE HYDROCHLORIDE Form and strength SOLUTION;INTRAVENOUS - 2500MG/50ML (50MG/ML) Sponsor EXELA PHARMA Submission history Latest submission status date: 2023-12-04 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.